-
Sitaxentan (Thelin▼) withdrawn due to hepatotoxicity.
-
No evidence of increased risk of febrile convulsions in children.
-
Saquinavir at a reduced dose for the first week of treatment
-
Differences in dose delivery between the pump device and dropper device for memantine.
-
Safety studies of Spiriva Respimat▼
-
Drug interactions involving CYP2D6, genetic variants, and variability in clinical response
-
Insufficient evidence to confirm a link between oral bisphosphonate use and an increased risk of oesophageal cancer.
-
Report of febrile promptly.
-
All healthcare professionals trained in inserting Implanon must make sure they are trained in using Nexplanon before the changeover.
-
Second year safety review
-
Suspension of the marketing authorisations of rosiglitazone (Avandia, Avandamet) recommended across the European Union.
-
Should not be used for cough under 18 years
-
Outline of the safety experience of these medicines in the UK from our proactive safety monitoring strategy.
-
Prescribers should remain vigilant with regards to the similarity of these 2 drug names.
-
Benefits of these medicines used in conjunction with inhaled corticosteroids (ICS) in the control of asthma symptoms in children outweigh any apparent risks.
-
Check pumps after MRI.
-
Risk of psychological and behavioural side effects.
-
Update on managing risk of misuse.
-
Erythema multiforme, Stevens Johnson syndrome and toxic epidermal necrolysis reported in association with isotretinoin - may result in hospitalisation, disability, life-threatening events, or death.
-
Aluminium can be leached from glass after contact with calcium gluconate solution, leading to a risk of exposure to aluminium. Accumulation of aluminium might have adverse effects on bone mineralisation and neurological deve…
-
European Medicines Agency has recommends the use of modafinil should be restricted to treat only sleepiness associated with narcolepsy - should no longer be used for obstructive sleep apnoea or chronic shift work sleep disor…
-
European Medicines Agency says further measures should be put in place to minimise the risk of adverse skin reactions.
-
Patients should be transferred to alternative bronchodilator therapy.
-
Risk of accidental overdose, particularly in infants and neonates.
-
Infusion reactions and hypersensitivity reactions have been reported commonly during treatment with Avastin.
-
Medication errors and inappropriate use of the rivastigmine transdermal patch have been reported, some of which resulted in overdose. Healthcare professionals should be aware of the correct use of rivastigmine, and should ad…
-
Quinine should only be considered when cramps cause regular disruption of sleep.
-
Best practice example of a patient information leaflet.
-
New reports of serious hypersensitivity reactions (including anaphylaxis) in patients receiving panitumumab, some of which were fatal.
-
Healthcare professionals should be aware of epidemiological data showing a small increased risk of fractures associated with the use of TCAs and SSRIs, and should take this risk into account in their discussions with patient…
-
A clinically significant interaction between carbapenems and valproic acid results in reduced valproate plasma concentrations with potential for inadequate seizure control. Concomitant use of these agents is not recommended,…
-
Epidemiological data suggest that the use of SSRIs in pregnancy, particularly in the later stages, may increase the risk of persistent pulmonary hypertension in the newborn. Healthcare professionals are encouraged to enquire…
-
There is an increased risk of myopathy associated with high-dose (80 mg) simvastatin. The 80-mg dose should be considered only in patients with severe hypercholesterolaemia and high risk of cardiovascular complications who h…
-
Zoledronic acid is associated with reports of renal impairment and renal failure, especially in patients with pre-existing renal dysfunction or other risk factors. Renal function should be measured before each dose, and pati…
-
There is a potential risk of fatal overdose due to confusion between lipid-based and non-lipid-based formulations of parenteral amphotericin B. These formulations are not interchangeable: prescribers, pharmacists, and nurses…
-
In light of the most recent evidence, the previous advice on the concomitant use of clopidogrel with proton pump inhibitors has now been modified. Use of either omeprazole or esomeprazole with clopidogrel should be discourag…
-
The solvent used in the preparation of Rifadin infusion has been reformulated. As a result, it can only be diluted with either dextrose 5% solution or sodium chloride 0·9% solution
-
Contraindicated in patients with any known current cancer
-
NHS Evidence Accreditation Scheme recognises organisations that demonstrate high standards in producing health or social care guidance.
-
The risk of developing progressive multifocal leukoencephalopathy (PML) with natalizumab increases after 2 years of therapy. Patients with multiple sclerosis should be informed of the risk before treatment, and again after 2…
-
Needs a summary
-
Recent epidemiological evidence suggests a possible small increased risk of congenital cardiac defects in association with fluoxetine in early pregnancy, similar to that seen with paroxetine. There are insufficient data to d…
-
The Food and Drug Administration (FDA) has received 35 reports of chondrolysis involving patients given continuous intra-articular infusions of local anaesthetics.
-
Risk of intraocular lens opacification.
-
A recent Europe-wide review of the safety information for alli has led to a number of updates, which bring the product information in line with that for Xenical.
-
Extension of the indication for nicotine replacement therapy (NRT) to include harm reduction.
-
Evidence indicates risks outweigh benefits.
-
No unexpected new safety issues have been identified from Yellow Card reports.
-
Gadolinium-containing contrast agents are associated with a varying degree of risk of nephrogenic systemic fibrosis. See advice below to minimise risk in the following vulnerable groups: patients with renal impairment; patie…
-
The design and content of the Patient Information Leaflets for methylphenidate products are being updated with the latest guidance on safe and effective use for patients and carers